On Tuesday, Shares of AbbVie Inc (NYSE:ABBV), added 2.34% and closed at 61.55 in the last trading session. The last trading range of the stock ranges between $60.40 and61.62. AbbVie (ABBV), a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NBIX), today announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis. The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain (dysmenorrhea, DYS) and non-menstrual pelvic pain (NMPP) associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale. The results were presented at the 72nd American Society for Reproductive Medicine Scientific Congress & Expo (ASRM) in Salt Lake City, as well as additional abstracts.
“Endometriosis is often characterized by chronic pelvic pain, and can have a significant impact on patient function and quality of life,” said Hugh S. Taylor, M.D., study investigator and Chair of the Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine. “The results presented today are encouraging for patients and demonstrate that Elagolix has the potential to be an important treatment option for women suffering from pain related to endometriosis.”
Exelon Corporation (NYSE:EXC), jumped 1.04% and closed at $33.09 in the last trading session. The last trading range of the stock ranges between 32.55and33.27. The company’s Market capitalization is $30.58 Billion with the total Outstanding Shares of 923.00 million. The U.S. Department of Energy’s (DOE’s) Argonne National Laboratory and Exelon have formed a five-year cooperative research and development agreement focused on identifying new technology and systems that will advance clean energy and contribute to the development of a next-generation energy grid.
“As the nation’s leading utility company and operator of the leading clean energy fleet, we have an exclusive responsibility to reimagine the energy grid and lead our industry in the exploration, development and deployment of the next generation of clean, diverse energy technologies,” said Chris Crane, Exelon president and CEO. “This partnership allows us to combine Exelon’s industry experts with the best minds in research to unlock new innovations and bring them to market for the benefit of our customers and the environment.”
“I believe this agreement shows the possibilities of bringing together the best of public science and private industry to make real breakthroughs that can impact the lives of people,” said Argonne Director Peter B. Littlewood. “Argonne has long believed in the power of delivering our groundbreaking science to consumers by partnering with industry, and it is an honor to have Exelon as one of those partners.”